Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
A legfontosabb adatok
- Ki végzi
- China National Center for Cardiovascular Diseases
- Hol
- Kína26 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 270 fő, tervezett
- Kezdés
- 2026. nov. 1.
- Várható befejezés
- 2029. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Alteplase
- Standard Anticoagulation
- A regiszteradat frissítve
- 2026. november 4.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a recent blood clot in the lungs (pulmonary embolism) that strains the heart but has not caused shock. It compares a low dose of alteplase plus blood thinners with blood thinners alone.
- Életkor
- 18 to 75 years
- Nem
- All sexes
- A betegség stádiuma
- Acute pulmonary embolism confirmed by a scan, with symptoms starting within 14 days. Intermediate-high risk: the right side of the heart is strained on a heart ultrasound or CT scan, and a heart blood test is raised. At least one warning sign is needed: systolic blood pressure ≤110 mmHg, heart rate ≥100 beats/min, or oxygen saturation <90%.
- Korábbi kezelés
- No clot-dissolving treatment within 30 days for this clot. No removal of the clot by catheter or surgery for this clot. No direct oral anticoagulant within 30 days. No current effective oral anticoagulant. No current dual antiplatelet therapy.
- Biomarker vagy leletérték
- Cardiac troponin, BNP or NT-proBNP above the local upper limit of normal.
A részvétel fő kizáró okai
- Shock, cardiac arrest or lasting low blood pressure from the clot
- Active bleeding, high bleeding risk, recent stroke, or recent surgery or injury
- Platelet count <100 × 10^9/L or INR >1.3
- Pregnancy or within 1 week after giving birth
- Body weight ≤40 kg (88 lb) or life expectancy <3 months
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 to 75 years
- Objectively confirmed acute pulmonary thromboembolism (PTE) with symptom onset within 14 days, based on at least one of the following:; Ventilation/perfusion lung scan showing at least one segmental or larger mismatched perfusion defect; Computed tomography pulmonary angiography (CTPA) or pulmonary angiography showing a filling defect or abrupt obstruction in a segmental or more proximal pulmonary artery
- Intermediate-high-risk PTE, with both of the following:; Right ventricular dysfunction (RVD) on echocardiography or CTPA. Echocardiographic RVD is defined by at least one of the following:(1) right ventricular dilation with RV/LV end-diastolic diameter ratio >1.0; (2) reduced right ventricular free-wall motion; (3) increased tricuspid regurgitation velocity;(4) tricuspid annular plane systolic excursion <16 mm; (5) tricuspid annular systolic velocity (S') <9.5 cm/s. CTPA evidence of RVD is defined as right ventricular dilation with RV/LV end-diastolic diameter ratio >1.0; Cardiac injury or heart failure biomarker above the local upper limit of normal, including cardiac troponin, BNP, or NT-proBNP
- Elevated risk of early death/hemodynamic collapse, indicated by at least one of the following high-risk features: Systolic blood pressure ≤110 mmHg, Heart rate ≥100 beats/min, Oxygen saturation (SpO₂) <90% (respiratory rate >20 breaths/min or arterial partial pressure of oxygen [PaO₂] <60 mmHg)
- Signed informed consent
Ki nem vehet részt
- Thrombolytic treatment within 30 days before randomization for the current episode of acute PE, including systemic or catheter-directed thrombolysis
- Catheter-directed mechanical thrombectomy or surgical pulmonary embolectomy before randomization for the current episode of acute PE
- Use of any direct oral anticoagulant within 30 days before randomization
- Current dual antiplatelet therapy
- High-risk PTE with hemodynamic instability, including cardiac arrest, obstructive shock, or persistent hypotension defined as systolic blood pressure <90 mmHg or a decrease of ≥40 mmHg from baseline lasting at least 15 minutes, after excluding hypotension caused by new-onset arrhythmia, hypovolemia, or sepsis
- Intermediate-low-risk PTE, defined as hemodynamically stable PE with only one of the following findings: right ventricular dysfunction on imaging or elevated cardiac biomarkers
- Low-risk PTE, defined as hemodynamically stable PTE without right ventricular dysfunction and without elevated cardiac injury or heart failure biomarkers
- Any other disease or condition that, in the investigator's judgment, would increase treatment risk
- Any contraindication to systemic thrombolysis, including:; Known hypersensitivity to alteplase, gentamicin, heparin, low-molecular-weight heparin, or any component of the study treatment; Active bleeding or high risk of bleeding; Known or suspected intracranial hemorrhage; Suspected subarachnoid hemorrhage or aneurysmal subarachnoid hemorrhage; Significant bleeding disorder within the previous 6 months; Known bleeding diathesis; Acute ischemic stroke or transient ischemic attack within the previous 6 months; Ophthalmic surgery within the previous 3 months, or abdominal, cardiac, thoracic, vascular, or orthopedic surgery or trauma within the previous 3 months; History of central nervous system disease or trauma, including tumor, aneurysm, head trauma, intracranial surgery, or spinal surgery; Platelet count <100 × 10\^9/L; International normalized ratio (INR) >1.3; Current effective oral anticoagulant treatment; Traumatic cardiopulmonary resuscitation; Infective endocarditis or pericarditis; Acute pancreatitis; Noncompressible vascular puncture; Severe uncontrolled hypertension, with systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg; Any other condition considered by the investigator to confer a high bleeding risk; Severe liver disease, including liver failure, cirrhosis, portal hypertension, esophageal varices, or active hepatitis; Gastrointestinal ulcer, esophageal varices, arterial aneurysm, or arteriovenous malformation within the previous 3 months; Tumor with bleeding tendency; Pregnancy or within 1 week postpartum; Diabetes with hemorrhagic retinopathy
- Body weight ≤40 kg
- Current participation in another interventional clinical trial
- Women of childbearing potential who are unwilling to use effective contraception or abstinence during the study
- Life expectancy <3 months or inability to complete 3-month follow-up
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Alteplase, a recombinant tissue plasminogen activator (rt-PA), is commonly used for thrombolytic treatment in patients with high-risk acute pulmonary thromboembolism (PTE), whereas the role of thrombolysis in intermediate-risk PTE remains controversial. This multicenter, randomized controlled trial will compare the efficacy and safety of reduced-dose alteplase (25 mg administered intravenously over 2 hours) plus standard anticoagulation with standard anticoagulation alone in patients with intermediate-risk PTE who have high-risk features.
A vizsgálat 2 csoportja
- Reduced-Dose Alteplase and Standard AnticoagulationMár használt kezelés, összehasonlításként
Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) and reduced-dose alteplase \[25 mg continuous intravenous infusion for 2 hours\]
Kezelés: Alteplase és Standard Anticoagulation
- Standard AnticoagulationMár használt kezelés, összehasonlításként
Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Reduced-Dose Thrombolysis in Intermediate-High Risk Pulmonary Embolism, a Multicenter, Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Illeszkedési kérdések
- Forrás: NCT07917078: ki vehet részt
- A regiszteradat frissítve
- 2026. november 4.